XNCR Xencor Inc
Price (delayed)
$19.89
Market cap
$1.23B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$1.29B
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in
Highlights
XNCR's revenue is up by 18% year-on-year but it is down by 18% since the previous quarter
The gross profit has increased by 18% YoY but it has decreased by 18% from the previous quarter
Xencor's debt has increased by 49% YoY
XNCR's quick ratio is down by 48% year-on-year and by 3.6% since the previous quarter
Key stats
What are the main financial stats of XNCR
Market
Valuations
Earnings
Shares outstanding
61.83M
Market cap
$1.23B
Enterprise value
$1.29B
Price to book (P/B)
2.17
Price to sales (P/S)
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.63
Revenue
$133.62M
EBIT
-$170.59M
EBITDA
-$158.17M
Free cash flow
$26.36M
Per share
Balance sheet
Liquidity
EPS
-$2.89
Free cash flow per share
$0.43
Book value per share
$9.15
Revenue per share
$2.17
TBVPS
$13.09
Total assets
$826.17M
Total liabilities
$263.63M
Debt
$87.68M
Equity
$564.33M
Working capital
$474.39M
Debt to equity
0.16
Current ratio
6.92
Quick ratio
6.63
Net debt/EBITDA
-0.36
Margins
Efficiency
Dividend
EBITDA margin
-118.4%
Gross margin
100%
Net margin
-132.7%
Operating margin
-129.8%
Return on assets
-20.6%
Return on equity
-28.2%
Return on invested capital
-21.2%
Return on capital employed
-22.9%
Return on sales
-127.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XNCR stock price
How has the Xencor stock price performed over time
Intraday
22.93%
1 week
13.72%
1 month
24%
1 year
-6.4%
YTD
-6.31%
QTD
5.07%
Financial performance
How have Xencor's revenue and profit performed over time
Revenue
$133.62M
Gross profit
$133.62M
Operating income
-$173.45M
Net income
-$177.37M
Gross margin
100%
Net margin
-132.7%
Xencor's net margin has shrunk by 61% QoQ and by 18% YoY
XNCR's operating margin has dropped by 53% since the previous quarter but it is up by 12% year-on-year
The company's net income fell by 39% YoY and by 33% QoQ
Xencor's operating income has decreased by 26% from the previous quarter and by 3.4% YoY
Growth
What is Xencor's growth rate over time
Valuation
What is Xencor stock price valuation
P/E
N/A
P/B
2.17
P/S
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.63
The EPS has decreased by 34% YoY and by 32% QoQ
XNCR's P/B is 23% below its 5-year quarterly average of 2.8 but 9% above its last 4 quarters average of 2.0
XNCR's equity is down by 17% year-on-year and by 8% since the previous quarter
XNCR's P/S is 29% below its 5-year quarterly average of 12.9 but 11% above its last 4 quarters average of 8.3
XNCR's revenue is up by 18% year-on-year but it is down by 18% since the previous quarter
Efficiency
How efficient is Xencor business performance
The ROS has shrunk by 62% QoQ and by 14% YoY
XNCR's ROE has plunged by 56% YoY and by 39% from the previous quarter
The ROA has contracted by 32% YoY and by 31% from the previous quarter
The ROIC has contracted by 32% from the previous quarter and by 23% YoY
Dividends
What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XNCR.
Financial health
How did Xencor financials performed over time
XNCR's total liabilities has surged by 166% year-on-year but it is down by 3.1% since the previous quarter
The company's current ratio fell by 48% YoY and by 2.3% QoQ
Xencor's debt is 84% lower than its equity
The debt to equity has soared by 78% YoY and by 7% from the previous quarter
Xencor's debt has increased by 49% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.